Predictors of Major Adverse Limb Events After Endovascular Iliac Stenting: a Real-world Cohort Study
A legfontosabb adatok
- Ki végzi
- I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio
- Hol
- Olaszország1 helyszín, 1 országbanVálassz országot a helyszínekhez
- Azonosító
- Állapot
- Toboroz
- Résztvevők
- 98 fő, tervezett
- Kezdés
- 2026. jún. 16.
- Tervezett befejezés
- 2026. júl. 16.
- A vizsgálat típusa
- Megfigyeléses
- A vizsgált kezelések
- Iliac stenting
- A regiszteradat frissítve
- 2026. június 30.
Ki vehet részt
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.
The trial is looking for adults with narrowed or blocked iliac arteries (the main arteries to the legs) who were treated with a stent. It looks back at their records to find what predicts serious leg problems afterwards.
- Életkor
- 18 years and older
- Nem
- Men and women
- A betegség stádiuma
- Peripheral artery disease with symptoms: leg pain when walking that limits daily life (Rutherford category 2-3) or chronic limb-threatening ischaemia (Rutherford category 4-6). The narrowing or blockage is in the common and/or external iliac artery and was shown on CT angiography, MR angiography or angiography.
- Korábbi kezelés
- Symptoms did not improve with optimal medical therapy. People must have had iliac artery stenting as the main treatment, on a lesion not treated before. People cannot join if this artery part had a stent before.
A részvétel fő kizáró okai
- Open surgery on the iliac arteries as the main treatment, such as aorto-bifemoral bypass or endarterectomy
- A stent placed before in the same iliac segment
- Treatment mainly for an aorto-iliac aneurysm (a bulging artery), including EVAR or fenestrated endografts
- Combined procedures with bypass surgery below the groin
- Missing clinical, procedure or follow-up data, or lost to follow-up
A regiszter feltételei, szó szerint
Mind a 12 feltétel megnézéseKevesebb
Ki vehet részt
- Adult patients aged ≥18 years, of both male and female sex
- Presence of haemodynamically significant stenosis or occlusion of the common iliac artery (CIA) and/or external iliac artery (EIA), documented by computed tomography angiography, magnetic resonance angiography, or diagnostic angiography
- Symptomatic peripheral artery disease, including lifestyle-limiting intermittent claudication (Rutherford category 2-3) or chronic limb- threatening ischaemia (CLTI; Rutherford category 4-6), refractory to optimal medical therapy
- Treatment with endovascular iliac artery stenting (covered or uncovered; balloon-expandable or self-expanding devices) as the primary revascularisation strategy
- De novo iliac lesions only
- Availability of complet
Ki nem vehet részt
- Primary open surgical revascularisation of the iliac axis (e.g., aorto- bifemoral bypass or endarterectomy)
- Previous stenting of the target iliac segment (in-stent restenosis cases excluded)
- Hybrid procedures with concomitant infrainguinal bypass surgery
- Aorto-iliac aneurysmal disease as the primary indication for treatment (including EVAR or fenestrated endografts)
- Incomplete clinical, procedural, or follow-up data preventing assessment of study endpoints
- Loss to follow-up without documented clinical outcomes
Ennek a vizsgálatnak nincs helyszíne itt: Egyesült Államok.
Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.
A vizsgálatról
Mit akar kideríteni a vizsgálat
Peripheral arterial disease involving the iliac arteries is a common manifestation of systemic atherosclerosis and a major cause of lifestyle-limiting claudication and chronic limb-threatening ischemia. Endovascular iliac artery stenting has become the preferred treatment strategy for most iliac lesions, including complex TransAtlantic Inter-Society Consensus II (TASC II) C and D lesions, owing to high technical success rates and lower perioperative morbidity compared with open surgical reconstruction.
A teljes eredeti leírásKevesebb
Despite widespread adoption of endovascular treatment, available evidence regarding predictors of major adverse limb events (MALE) after iliac artery stenting remains limited, particularly in unselected real-world populations with substantial comorbidity burden. Patient-related factors, including frailty, may contribute to post-procedural outcomes in addition to lesion-related characteristics.
This retrospective single-center cohort study will evaluate clinical outcomes following endovascular iliac artery stenting in consecutive adult patients treated at IRCCS Galeazzi-Sant'Ambrogio Hospital, Milan, Italy. The study will assess the occurrence of major adverse limb events (MALE), primary patency, peri-procedural complications, target lesion revascularization, restenosis or occlusion, and all-cause mortality. Clinical, anatomical, and procedural factors associated with adverse limb outcomes, including frailty assessed by the modified five-item Frailty Index (mFI-5), will also be investigated.
A vizsgált kezelések
- Iliac stenting
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- Predictors of Major Adverse Limb Events After Endovascular Iliac Stenting: a Real-world Cohort Study (PREMISE-ILIAC Study)
- MI-összefoglaló
- A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
- A regiszteradat frissítve
- 2026. június 30.